Articles

Videos

Podcasts

Clinical Role

In a presentation at the Community Oncology Alliance 2021 Virtual Conference, Jeff Sharman, MD, summarized the most important developments in care for CLL.

Novel Treatments for Chronic Lymphocytic Leukemia Result in Improved Outcomes, Lower Adverse Effects

Over the past 18 months, the FDA has approved 4 new regimens for HER2-positive metastatic disease.

New Therapies for HER2-Positive Metastatic Breast Cancer Show Promise, Although Research on Sequencing is Needed

A new study published in Nature Communications used artificial intelligence (AI) to identify 3 new multiple sclerosis (MS) subtypes, which may help identify which individuals are more likely to have disease progression, according to the authors. 

Artificial Intelligence Identifies Novel Multiple Sclerosis Subtypes

The researchers found that patients who reduced their calorie intake by 10% or more and adopted a moderate exercise program immediately after their diagnosis had, on average, 70% less chance of having lingering leukemia cells after a month of chemotherapy than those not on the diet-and-exercise regimen.

Study: Mild Diet, Exercise Improves Survival for Young People With Leukemia

In the United States, non–small cell lung cancer accounts for 80% to 85% of all lung cancers, with most patients initially diagnosed with advanced or metastatic disease.

New Non–Small Cell Lung Cancer Therapies Coming in 2021

The first step toward operationalizing the uptake of biosimilars is having a program-level discussion that not only describes what biosimilars are, but also assesses how they impact the bottom line and could get incorporated into treatment plans.

Approaching the Process of Operationalizing Biosimilars in Cancer Care

Opdivo-based combinations show benefit for patients with esophageal cancer who are often diagnosed after their disease has spread and would benefit from new therapeutic options.

Nivolumab Combinations Demonstrate Superior Survival Benefit in Esophageal Squamous Cell Carcinoma

Findings from the phase 3 ASCENT trial demonstrate a clinically meaningful 57% reduction in the risk of disease worsening or death for patients receiving sacituzumab govitecan. 

FDA Approves Sacituzumab Govitecan for Adults with Triple-Negative Breast Cancer

Health System Owned Specialty Pharmacy Alliance issues open letter outlining three needed industry actions to improve patient care and outcomes.

Health System Owned Specialty Pharmacy Alliance: A Voice for Integrated Specialty Pharmacies

In April 2020, colonoscopy screenings declined from 15.1 per 10,000 beneficiaries to 0.9, a 95% difference.